About Aiforia
Aiforia is a company based in Helsinki (Finland) founded in 2014. Aiforia has raised $22.99 million across 7 funding rounds from investors including European Union, Business Finland and Epredia. The company has 3 employees as of December 31, 2022. Aiforia offers products and services including Aiforia® Breast Cancer Suite, Aiforia® Lung Cancer Suite, Aiforia® Prostate Cancer Suite, Aiforia® Colon Suite, and Aiforia® Gastric Suite. Aiforia operates in a competitive market with competitors including Viz.ai, PathAI, Deepcell, Aignostics and Deciphex, among others.
- Headquarter Helsinki, Finland
- Employees 3 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aiforia Technologies Oy Class A
-
Annual Revenue
$2.96 M (USD)18.93as on Dec 31, 2024
-
Net Profit
-$12.41 M (USD)7.57as on Dec 31, 2024
-
EBITDA
-$12.62 M (USD)3.53as on Dec 31, 2024
-
Total Equity Funding
$22.99 M (USD)
in 7 rounds
-
Latest Funding Round
$4.92 M (USD), Post-IPO
Dec 12, 2025
-
Investors
European Union
& 7 more
-
Employee Count
3
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aiforia
Aiforia is a publicly listed company on the OMXHEX with ticker symbol AIFORIA in Finland, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aiforia
Aiforia offers a comprehensive portfolio of products and services, including Aiforia® Breast Cancer Suite, Aiforia® Lung Cancer Suite, Aiforia® Prostate Cancer Suite, Aiforia® Colon Suite, and Aiforia® Gastric Suite.
AI for analyzing breast cancer images in diagnostics.
AI for lung cancer image screening and analysis.
AI platform for prostate cancer diagnostics and reporting.
AI for colon cancer image analysis in clinical settings.
AI tools for gastric cancer diagnostics and visualization.
Tool for creating custom AI models in pathology research.
People of Aiforia
Unlock access to complete
Unlock access to complete
Funding Insights of Aiforia
Aiforia has successfully raised a total of $22.99M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.92 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aiforia
Aiforia has secured backing from 8 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include European Union, Business Finland and Epredia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Capital is invested in early-stage disruptors for global ventures.
|
Locked | Locked | Locked | |
|
Early-stage investments are directed toward disruptive technologies and innovations.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Aiforia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aiforia
Investment portfolio details for Aiforia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aiforia
Detailed financials for Aiforia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aiforia Comparisons
Peer comparison for Aiforia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aiforia
Aiforia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viz.ai, PathAI, Deepcell, Aignostics and Deciphex, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI and cloud-powered software for stroke care coordination is developed.
|
|
| Locked | Locked | Locked |
Provider of AI-based solutions for clinical diagnosis of cancer and other diseases
|
|
| Locked | Locked | Locked |
AI-powered single cell classification and isolation technology for clinical research
|
|
| Locked | Locked | Locked |
AI-based pathology diagnostic software is provided for medical analysis.
|
|
| Locked | Locked | Locked |
Digital pathology software is developed for clinical and veterinary productivity.
|
|
| Locked | Locked | Locked |
Provides image analysis and data mining solutions for quantitative digital pathology in the healthcare industry
|
Detailed competitors of Aiforia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aiforia
Complete news archive for Aiforia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aiforia
Aiforia was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Aiforia is headquartered in Helsinki, Finland.
Aiforia is a funded company, having raised a total of $22.99M across 7 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Aiforia is 3.
Annual revenue of Aiforia is $2.96M as on Dec 31, 2024.
Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas. It provides analysis of digital pathology images for pathologists and researchers. The products are aiforia create, aiforia on-demand, and aiforia cloud.
Aiforia's top competitors include Aignostics, Deciphex and Pictor Labs.
Aiforia offers Aiforia® Breast Cancer Suite, Aiforia® Lung Cancer Suite, Aiforia® Prostate Cancer Suite, Aiforia® Colon Suite, and 2 more products and services.
Yes, Aiforia is publicly traded on OMXHEX under the ticker symbol AIFORIA.
Aiforia has 8 investors. Key investors include European Union, Business Finland, Epredia, Ascend Capital Partners, and ACME Capital.
The ticker symbol of Aiforia is AIFORIA on OMXHEX.